Memantine for the treatment of dementia: a review on its current and future applications

J Folch, O Busquets, M Ettcheto… - Journal of …, 2018 - content.iospress.com
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in
the brain of extracellular amyloid-protein (A) and intracellular neurofibrillary tangles …

Memantine for dementia

R McShane, AA Sastre… - Cochrane database of …, 2006 - cochranelibrary.com
Memantine for dementia - McShane, R - 2006 | Cochrane Library Skip to Content Cookies Our
site uses cookies to improve your experience. You can find out more about our use of cookies …

[PDF][PDF] Memantine for dementia

R McShane, MJ Westby, E Roberts… - … Database Syst Rev, 2019 - cochranelibrary.com
Cochrane Page 1 Cochrane Library Cochrane Database of Systematic Reviews Memantine
for dementia (Review) McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L …

Evidence and gap map of studies assessing the effectiveness of interventions for people with disabilities in low‐and middle‐income countries

A Saran, H White, H Kuper - Campbell Systematic Reviews, 2020 - Wiley Online Library
Background There are approximately 1 billion people in the world with some form of
disability. This corresponds to approximately 15% of the world's population (World Report on …

The role of NMDA receptor in neurobiology and treatment of major depressive disorder: evidence from translational research

M Amidfar, M Woelfer, GZ Reus, J Quevedo… - Progress in Neuro …, 2019 - Elsevier
There is accumulating evidence demonstrating that dysfunction of glutamatergic
neurotransmission, particularly via N-methyl-d-aspartate (NMDA) receptors, is involved in …

An update on NMDA antagonists in depression

B Pochwat, G Nowak, B Szewczyk - Expert review of …, 2019 - Taylor & Francis
Introduction: Current antidepressant therapies exhibit low therapeutic efficiency and delayed
onset of antidepressant action. Thus, the search for better acting agents is a continuous …

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder

RL Dean, C Hurducas, K Hawton… - Cochrane Database …, 2021 - cochranelibrary.com
Background Many studies have recently been conducted to assess the antidepressant
efficacy of glutamate modification in mood disorders. This is an update of a review first …

Memantine in neurological disorders–schizophrenia and depression

K Czarnecka, J Chuchmacz, P Wójtowicz… - Journal of Molecular …, 2021 - Springer
Memantine is used in Alzheimer's disease treatment as a non-competitive modern-affinity
strong voltage-dependent N-methyl-D-aspartate receptor antagonist. The fundamental role …

Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial

S Arabzadeh, E Hakkikazazi, N Shahmansouri… - Journal of affective …, 2018 - Elsevier
Background Major depressive disorder (MDD) exerts a high health and financial burden on
society. The conventional pharmacotherapies for MDD are partially effective and the …

GluN2A and GluN2B N-Methyl-D-Aspartate receptor (NMDARs) subunits: their roles and therapeutic antagonists in neurological diseases

AD Ladagu, FE Olopade, A Adejare, JO Olopade - Pharmaceuticals, 2023 - mdpi.com
N-methyl-d-aspartate receptors (NMDARs) are ion channels that respond to the
neurotransmitter glutamate, playing a crucial role in the permeability of calcium ions and …